Preferred Label : Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific
Prostate Cancer Vaccine BPX-201;
NCIt synonyms : Adenovector-transduced AP1903-inducible iMC-expressing Autologous PSMA-specific Prostate
Cancer Vaccine BPX-201;
NCIt definition : A genetically-modified, dendritic cell-based (DCs) vaccine in which the autologous
cells are transduced with an adenoviral vector expressing the tumor antigen prostate-specific
membrane antigen (PSMA) and a fusion protein composed of synthetic ligand inducible
adjuvant iMC composed of a drug-inducible costimulatory CD40 receptor (iCD40) and
the adaptor protein MyD88, with potential immunomodulating and antineoplastic activities.
The iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to the FK506
modified drug-binding protein 12 (FKBP12). Upon intradermal administration of BPX-201,
these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination,
the dimerizing agent AP1903 is administered. AP1903 binds to the drug binding domain,
leading to iMC oligomerization and activation of iCD40 and MyD88-mediated signaling
in iMC-expressing DCs. This signaling pathway activates the DCs and stimulates a cytotoxic
T-lymphocyte (CTL) response against host tumor cells that express PSMA. PSMA, a glycoprotein
secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer
cells and is used as a tumor marker for both diagnosis and treatment evaluation. MyD88
is involved in interleukin 1 receptor (IL1R) and toll-like receptor (TLR) signaling.;
Molecule name : BPX-201;
NCI Metathesaurus CUI : CL447413;
Origin ID : C106242;
UMLS CUI : C3827147;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
